The prevalence of fungal infections is increasing along with the aggravating burden
of diabetes worldwide. Candida and Aspergillus are among the most common fungal pathogens,
while others are rarer and easy to be ignored such as Mucor. Pulmonary mucormycosis
is a fatal opportunistic fungal infection caused by Mucor, of which Cunninghamella is reported to have the highest mortality.
1
Amphotericin B and its lipid-associated formulation are the currently recommended
treatment, but it is also reported that posaconazole, a novel triazole broad-spectrum
antifungal oral preparation, can be used as a combined treatment for refractory mucormycosis.
2
Herein, we reported a diabetic patient with pulmonary mucormycosis caused by Cunninghamella and successful treatment by posaconazole to improve awareness and share the experience
of clinical diagnosis and treatment of pulmonary mucormycosis caused by Cunninghamella.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of the Medical SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Isavuconazole in a successful combination treatment of disseminated mucormycosis in a child with acute lymphoblastic leukaemia and generalized haemochromatosis: a case report and review of the literature.Mycopathologia. 2019; 184: 81-88
- Cunninghamella bertholletiae infection in children: review and report of 2 cases with disseminated infection.J Pediatr Hematol Oncol. 2014; 36: e109-e114
- Epidemiology and outcome of zygomycosis: a review of 929 reported cases.Clin Infect Dis. 2005; 41: 634-653
- Molecular identification of zygomycetes from culture and experimentally infected tissues.J Clin Microbiol. 2006; 44: 340-349
- Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.Antimicrob Agents Chemother. 2008; 52: 2636-2638
Article info
Publication history
Published online: March 19, 2022
Accepted:
October 21,
2021
Received:
April 23,
2021
Identification
Copyright
© 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.
